NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer. | Lancet Oncol;12(1): 16-7, 2011 Jan. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

Nursing VHL Search Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search

NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer.

Holden, Joanne; Garrett, Zoe; Stevens, Andrew.

Lancet Oncol ; 12(1): 16-7, 2011 Jan.

Article in En | MEDLINE | ID: mdl-21249723

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Receptor, ErbB-2/antagonists & inhibitors; Stomach Neoplasms/drug therapy; Antibodies, Monoclonal, Humanized; Health Care Costs; Humans; Practice Guidelines as Topic; Quality-Adjusted Life Years; Receptor, ErbB-2/analysis; Stomach Neoplasms/chemistry; Trastuzumab

Search on Google

Database: MEDLINE Main subject: Stomach Neoplasms / Receptor, ErbB-2 / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Guideline Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2011 Type: Article

Search on Google

Database: MEDLINE Main subject: Stomach Neoplasms / Receptor, ErbB-2 / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Guideline Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2011 Type: Article